# Sitting on a Cash Pile 14.0? Pay Attention to SURF, the Options Market is Very Active

Live Trading News is an independent financial media publication. Masthead: Live Trading News. Parent: Knightsbridge Group. Product cousin: KXCO (kxco.ai). Coverage: markets, policy, AI, quantum, blockchain, FX, biotech, ASEAN. New stories are signed ML-DSA-65 and anchored on Armature L1; articles published before the platform launch are not signed. Nothing on the site is investment advice.

Canonical HTML: https://www.livetradingnews.com/sitting-on-a-cash-pile-14-0-pay-attention-to-surf-the-market-is-very-active
Last modified: 2021-05-19

---

By Paul Ebeling · 2021-05-19
Tags: Shayne Heffernan on Investments, buy, resistance, cash, support, Bullish, Paul Ebeling, surf, Todays Trade Ideas
Signed: no (published before platform launch).
Nothing in this article is investment advice.

#cash #bullish #buy

[$SURF](https://finance.yahoo.com/quote/SURF?p=SURF&.tsrc=fin-srch)

Surface Oncology Inc. ([NASDAQ:SURF](NASDAQ:SURF)) reversed on 17 May at 8.46. Thus, garnering an early Cash Pile Buy signal with a 1yr price target at 16.90/share

The consensus target is at 16.40, and the stock is trading pre-market Wednesday at 9.00/share with in its 52 wk trading range of 3.12 - 14.40.

The Key support is at 7.51, the Key resistance is at 10.50 and 2 of our 3 Key technical indicators have turned Very Bullish in here.

![](https://livetradingnews-media.nyc3.digitaloceanspaces.com/wp/placeholder.svg)

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. 

The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells.

SURF also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. 

Surface Oncology, Inc. was incorporated in Y 2014 and is HQ'd in Cambridge, Massachusetts.

Have a healthy day, Keep the Faith!

#SURF, #cash, #bullish, #buy, #support, #resistance,

---

This Markdown mirrors https://www.livetradingnews.com/sitting-on-a-cash-pile-14-0-pay-attention-to-surf-the-market-is-very-active. The HTML page is canonical.
Site index for AI clients: https://www.livetradingnews.com/llms.txt